Nektar Therapeutics

Name: Nektar Therapeutics standardized financial statements, quarterly
Creator: Listed

NKTRNasdaqCIK 906709HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$10.1m, Q2 FY2026

Operating income−$42.3m, Q2 FY2026

Net income−$40.6m, Q2 FY2026

Nektar Therapeutics, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	24.1	23.9	21.6	23.5	24.1	29.2	10.5	11.2	11.8	21.8	10.9	10.1
Cost of revenue	$m	12.4	7.3	8.5	9.7	4.4	8.0	0.0	0.0	0.0	0.0	not reported	not reported
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	24.1	29.9	27.4	29.7	35.0	28.7	30.5	29.9	27.3	29.7	35.7	39.1
Operating income	$m	(44.9)	(33.5)	(35.4)	(49.8)	(34.3)	14.3	(44.5)	(36.2)	(31.7)	(27.7)	(39.1)	(42.3)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	(0.1)	(0.0)	(0.0)	0.0	0.0	(0.3)	0.1	(0.2)	(0.0)	0.0	0.1	0.0
Net income	$m	(45.8)	(42.1)	(36.8)	(52.4)	(37.1)	7.3	(50.9)	(41.6)	(35.5)	(36.1)	(44.9)	(40.6)
Diluted EPS	$ per share	(0.24)	not reported	(0.19)	(3.76)	(2.66)	not reported	(3.62)	(2.95)	(1.87)	not reported	(1.82)	(1.23)
Basic EPS	$ per share	(0.24)	not reported	(0.19)	(3.76)	(2.66)	not reported	(3.62)	(2.95)	(1.87)	not reported	(1.82)	(1.23)

Balance sheet

Cash and equivalents$39.3m, Q2 FY2026

Shareholders' equity$903.1m, Q2 FY2026

Nektar Therapeutics, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	64.9	35.3	48.6	27.9	30.1	44.3	38.9	43.0	41.0	15.1	150	39.3
Current assets	$m	399	331	320	295	286	261	230	187	281	266	589	739
Total assets	$m	442	398	396	343	308	304	256	208	301	280	763	1,095
Current liabilities	$m	52.1	51.3	52.4	57.3	67.6	61.4	70.9	71.4	66.3	53.5	57.7	71.0
Total liabilities	$m	283	267	269	264	259	243	243	232	216	191	187	192
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	159	131	127	79.7	48.9	60.7	13.7	(24.2)	85.1	89.8	576	903

Cash flow

Operating cash flow−$75.8m, Q2 FY2026

Capital expenditure$94.0k, Q2 FY2026

Share repurchases$0, Q4 FY2025

Nektar Therapeutics, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(42.1)	(47.0)	(47.9)	(37.7)	(43.9)	(46.2)	(49.1)	(45.7)	(48.8)	(65.0)	(44.3)	(75.8)
Capital expenditure	$m	0.0	0.2	0.2	0.2	0.7	0.5	0.0	0.0	0.1	0.0	0.0	0.1
Share repurchases	$m	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported

Diluted shares (weighted)33.05m, Q2 FY2026

Nektar Therapeutics, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	188	189	190	190	195	13.9	13.9	14.1	14.1	18.9	24.7	33.1

Shares outstanding: 34.14m at Aug 7, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. Listed shows no prices and gives no investment advice.